| 商品名称 | Votrient |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Carcinoma, Renal Cell |
| 通用名/非专利名称 | pazopanib |
| 活性成分 | pazopanib |
| 产品号 | EMEA/H/C/001141 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | L01XE11 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2010/06/14 |
| 上市许可开发者/申请人/持有人 | Novartis Europharm Limited |
| 人用药物治疗学分组 | Antineoplastic agents |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2010/06/14 |
| 欧盟委员会决定日期 | 2025/10/28 |
| 修订号 | 32 |
| 治疗适应症 | Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2018/05/08 |
| 最后更新日期 | 2025/10/28 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/votrient |